CoChat

Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids

Open access
Han, Yuling, Yang, Liuliu, Duan, Xiaohua, Duan, Fuyu, Nilsson-Payant, Benjamin E., Yaron, Tomer M., Wang, Pengfei, Tang, Xuming, Zhang, Tuo, Zhao, Zeping, Bram, Yaron, Redmond, David, Houghton, Sean, Nguyen, Duc, Xu, Dong, Wang, Xing, Uhl, Skyler, Huang, Yaoxing, Johnson, Jared L., Xiang, Jenny, Wang, Hui, Pan, Fong Cheng, Cantley, Lewis C., tenOever, Benjamin R., Ho, David D., Evans, Todd, Schwartz, Robert E., Chen, Huanhuan Joyce, Chen, Shuibing · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
PreprintCited by 106

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Summary Paragraph: The SARS-CoV-2 virus has caused already over 3.5 million COVID-19 cases and 250,000 deaths globally. There is an urgent need to create novel models to study SARS-CoV-2 using human disease-relevant cells to understand key features of virus biology and facilitate drug screening. As primary SARS-CoV-2 infection is respiratory-based, we developed a lung organoid model using human pluripotent stem cells (hPSCs) that could be adapted for drug screens. The lung organoids, particularly aveolar type II cells, express ACE2 and are permissive to SARS-CoV-2 infection. Transcriptomic analysis following SARS-CoV-2 infection revealed a robust induction of chemokines and cytokines with little type I/III interferon signaling, similar to that observed amongst human COVID-19 pulmonary infections. We performed a high throughput screen using hPSC-derived lung organoids and identified FDA-approved drug candidates, including imatinib and mycophenolic acid, as inhibitors of SARS-CoV-2 entry. Pre- or post-treatment with these drugs at physiologically relevant levels decreased SARS-CoV-2 infection of hPSC-derived lung organoids. Together, these data demonstrate that hPSC-derived lung cells infected by SARS-CoV-2 can model human COVID-19 disease and provide a valuable resource to screen for FDA-approved drugs that might be repurposed and should be considered for COVID-19 clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.05.05.079095

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 106

Metadata

Authors
Han, Y., Yang, L., Duan, X., Duan, F., Nilsson-Payant, B. E., Yaron, T. M., Wang, P., Tang, X., Zhang, T., Zhao, Z., Bram, Y., Redmond, D., Houghton, S., Nguyen, D., Xu, D., Wang, X., Uhl, S., Huang, Y., Johnson, J. L., Xiang, J., Wang, H., Pan, F. C., Cantley, L. C., tenOever, B. R., Ho, D. D., Evans, T., Schwartz, R. E., Chen, H. J., & Chen, S.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2020-05-05
OpenAlex
W3021120315
Cited by
106
References
2
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids. https://app.cochat.ai/papers/10.1101/2020.05.05.079095
The paper
Han, Y., Yang, L., Duan, X., Duan, F., Nilsson-Payant, B. E., Yaron, T. M., Wang, P., Tang, X., Zhang, T., Zhao, Z., Bram, Y., Redmond, D., Houghton, S., Nguyen, D., Xu, D., Wang, X., Uhl, S., Huang, Y., Johnson, J. L., . . . Chen, S. (2020). Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2020.05.05.079095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.